Evidence map›Paper›PMID 41198811›Full record

ArticleScientific reports2025

Exploring the mechanism of PFTrDA on human hepatic metabolic diseases based on network toxicology and molecular docking.

Zengqiang Li, Chaoqun Guo, Tingjie Wang, Lijun Weng

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zengqiang LiDepartment of Anesthesiology, Anesthesiology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China. lizengqiang0608@163.com.
Chaoqun GuoDepartment of Ophthalmology, Fuzhou Second General Hospital, Fuzhou, 350000, China.
Tingjie WangDepartment of Anesthesiology, Anesthesiology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Lijun WengDepartment of Anesthesiology, Anesthesiology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.

Funding

Natural Science Foundation of Fujian Province 2023J01563
6 · The paper itself

Abstract

One of the most common and extensively disseminated endocrine disrupting chemicals (EDCs) is perfluorotridecanoic acid (PFTrDA), which is used extensively in food packaging and has been linked to the development of metabolic disorders. Human health and food safety are intimately intertwined. Thus, as exemplary hepatic metabolic diseases, we selected liver cancer and nonalcoholic fatty liver disease (NAFLD). By employing advanced network toxicology and molecular docking techniques, we have discovered potential molecular pathways underlying these two diseases. We pinpointed the potential targets associated with the disease by leveraging databases including PubChem, ADEMTlab3.0, Swiss Target Prediction, OMIM, and GeneCards. To identify the primary targets that were most closely connected to these metabolic disorders, we also used Cytoscape software and STRING analysis. Furthermore, the David database's Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were used to perform enrichment analysis of these key targets. Lastly, we used AutoDock Vina molecular docking to confirm PFTrDA's binding affinity to these target proteins. Our results imply that PFTrDA may regulate fatty acid metabolism and impact signal transduction pathways, which may lead to the onset of metabolic disorders. It's interesting that we also discovered links between liver cancer and NAFLD. In summary, this study offers a theoretical foundation for comprehending the molecular mechanisms behind PFTrDA toxicity and lays forth a basic theoretical framework for the creation of therapeutic and preventative approaches for hepatic metabolic disorders linked to PFTrDA.

Indexed as

Liver NeoplasmsMolecular Docking SimulationNon-alcoholic Fatty Liver DiseaseHumansSignal TransductionCancerMolecular dockingNAFLDNetwork toxicologyPFTrDA

Identifiers

PMID41198811
PMCPMC12592707

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.